Precautions and risks of sudden discontinuation of Seleniso (Silvio) after taking it for six days

Selinexor is a selective nuclear export inhibitor. It mainly blocks the function of nuclear export protein XPO1 and inhibits the abnormal distribution of multiple tumor-related proteins in cancer cells, thereby exerting anti-tumor effects. It is usually used for the treatment of patients with multiple myeloma, diffuse large B cell lymphoma, etc. This drug generally needs to be taken regularly for a long time under the guidance of a doctor. Sudden discontinuation may affect the maintenance of drug efficacy and even disease control.

If selinesol is suddenly discontinued after six days of taking it, the main risks include disease rebound or progression. Due to the short half-life of the drug, the effective drug concentration in the body will drop rapidly after stopping the drug, which may lead to the reactivation of cancer cells, aggravation of symptoms or recurrence of the disease. In addition, some patients may be at risk of developing drug resistance due to sudden discontinuation of the drug, which may affect the efficacy of the drug when used again.

If selinesol must be discontinued due to adverse reactions or other reasons, the attending physician should be contacted as soon as possible. Doctors will evaluate whether dosage adjustment, supportive care, or other alternatives are needed based on the patient's specific situation. If the medication is discontinued due to side effects, auxiliary medication may be needed to relieve symptoms (such as antiemetics, fluid rehydration, blood picture correction, etc.), and then whether to resume treatment will be evaluated after symptoms improve. Do not decide to stop or restart medication on your own, as this may affect efficacy and safety.

For patients who are receiving selinesol treatment, it is recommended to establish a complete medication record and strictly follow the doctor's instructions. If you need to stop or adjust medication, a professional doctor should formulate a plan based on your condition and test results. At the same time, regular reexaminations should be maintained after stopping the drug, to monitor tumor indicators, blood images and organ functions to detect changes in the condition in a timely manner. For patients undergoing long-term treatment, attention should also be paid to psychological and nutritional support to ensure a balance between efficacy and quality of life to the greatest extent possible.

Reference link:https://www.drugs.com